Please assess the completion status of the following clinical trial:

Trial Title: Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 18-75 years old, with symptomatic PAH~* PAH belonging to the following subgroups of the updated Dana Point Clinical Classification Group 1 (Idiopathic, or Heritable, or Drug or toxin induced, or Associated (APAH) with Connective tissue disease, Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair, or HIV infection)~* Documented hemodynamic diagnosis of PAH by right heart catheterization, performed at any time prior to Screening~* Six minute walk distance (6MWD) between 50 and 450 m at Screening within 2 weeks prior to the Baseline Visit~* Signed informed consent~Exclusion Criteria:~* Patients with pulmonary hypertension (PH) in the Updated Dana Point Classification Groups 2-5, and PAH Group 1 subgroups that are not covered by the inclusion criteria~* Patients who have received prostacyclin or its analogs within 1 month before Baseline Visit, or are scheduled to receive any of these compounds during the trial~* Patients with moderate or severe obstructive lung disease~* Patients with moderate or severe restrictive lung disease~* Patients with moderate or severe hepatic impairment (Child-Pugh B and C)~* Patients with documented left ventricular dysfunction~* Patients with severe renal insufficiency~* Patients with BMI \<18.5 Kg/m2~* Patients who are receiving or have been receiving any investigational drugs within 1 month before the Baseline Visit~* Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements, in particular with 6MWT~* Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training~* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements~* Life expectancy less than 12 months~* Females who are lactating or pregnant or plan to become pregnant during the study~* Known hypersensitivity to any of the excipients of the drug formulations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed

Based on this trial design, predict the completion outcome and termination type (if applicable).